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Objectives: Health economics analysis plans (HEAPs) currently lack consistency, with uncertainty surrounding appropriate
content. We aimed to develop a list of essential items that should be included in HEAPs for economic evaluations conducted
alongside randomized trials.
Methods: A list of potential items for inclusion was developed by examining existing HEAPs. An electronic Delphi survey was
conducted among professional health economists. Respondents were asked to rate potential items from 1 (least important) to
9 (most important), suggest additional items, and comment on proposed items (round 1). A second survey (round 2) was
emailed to participants, including the participant’s own scores from round 1 along with summary results from the whole
panel; participants were asked to rerate each item. Consensus criteria for inclusion in the final list were predefined as.70% of
participants rating an item 7-9 and ,15% rating it 1-3 after round 2. A final item selection meeting was held to scrutinize the
results and adjudicate on items lacking consensus.
Results: 62 participants completed round 1 of the survey. The initial list included 72 potential items; all 72 were carried
forward to round 2, and no new items were added. 48 round 1 respondents (77.4%) completed round 2 and reached
consensus on 53 items. At the final meeting, the expert panel (n = 9) agreed that 58 items should be included in the essential
list, moved 9 items to an optional list, and dropped 5 items.
Conclusions: Via expert consensus opinion, this study identified 58 items that are considered essential in a HEAP.
Keywords: analysis plans, bias, economic evaluation.
VALUE HEALTH. 2020; -(-):-–-Introduction
The use of statistical analysis plans (SAPs) is an accepted means
of reducing bias in randomized controlled trials (RCTs) by mini-
mizing selective reporting of results and undeclared post hoc
analyses. A SAP is defined as "a document that contains a more
technical and detailed elaboration of the principal features of the
analysis described in the protocol, and includes detailed proced-
ures for executing the statistical analysis of the primary and sec-
ondary variables and other data".1
Economic evaluations are frequently conducted alongside
RCTs, providing evidence of the value for money that a health
intervention offers to inform funding allocation decisions. SAPs
are used routinely in RCTs by trial statisticians. However, in
contrast to SAPs, health economics analysis plans (HEAPs) are not
universally implemented by health economists, are not mandated
in SPIRIT (Standard Protocol Items: Recommendations for Inter-
ventional Trials2) or other such guidelines (eg, 1), and lack15 - see front matter Copyright ª 2020, ISPOR–The Professional Society for
cess article under the CC BY license (http://creativecommons.org/licenses/bstandardization in their content. A recent survey of current prac-
tice found that only around 30% of 28 responding clinical trials
units in the UK always use some form of HEAP, and there was little
consistency in the approach taken by different units.3
In October 2015, a workshop funded by the Medical Research
Council was held in Bristol, UK, to provide a forum in which issues
around current practice and opinions on the appropriate use of
HEAPs could be discussed. The 50 participants (who were mainly
UK-based health economists) contributed to various group dis-
cussions including a debate on the appropriate content of HEAPs,
which highlighted the range of opinions and the need to achieve
consensus. Feedback from the workshop suggested that most
participants considered that developing a HEAP had some merits
in trial-based economic evaluations. Furthermore, there was a
recognized need for robust guidance on the content of HEAPs.4
Guidance for the content of SAPs has recently been developed
and identifies 61 items that are considered essential for inclusion.5
It also provides a consensus opinion that some additionalHealth Economics and Outcomes Research. Published by Elsevier Inc. This is an
y/4.0/).
2 VALUE IN HEALTH - 2020trial-based analyses, including statistical procedures for the health
economics component of the study, should not be included within
the SAP. Prespecified analysis plans have been used in other areas
of economics6; however, guidance on preparing HEAPs for eco-
nomic evaluations conducted alongside RCTs and their appro-
priate content is currently sparse.7 HEAPs are rarely published; the
few examples are typically standalone appendices8 or part of a
SAP,9 and their content varies. This article aims to specify the
preferred content of HEAPs for use with RCTs using a consensus
approach to identify the appropriate items. To help prevent bias in
trial-based economic evaluations, it is important that good-quality
HEAPs are developed and adopted more widely.Methods
Ethics approval for the study was granted by the Faculty of
Health Sciences Research Ethics Committee of the University of
Bristol (application reference number: 54903). Analyses were
carried out using Microsoft Excel 2016.
Consensus on the essential items for inclusion in a HEAP was
sought using Delphi methodology,10 which has been widely
employed in recent years in a number of different healthcare
contexts.11 In a Delphi study, a panel of experts in the field is asked
to express an opinion on the question being studied. These results
are summarized at a group level and participants are asked to
reconsider their original opinions in light of group feedback. The
process is repeated iteratively until a prespecified consensus point
is reached. Participants generally remain anonymous and inde-
pendent of one another, ensuring that more assertive group voices
do not dominate the decision-making process.
Identification of “Long List” of Items and Development of
the Delphi Survey
Current examples of HEAPs were solicited from health econ-
omists registered on the HEALTHECON-ALL mailing list (approxi-
mately 2500 international members with diverse backgrounds in
terms of their level of experience, work setting, and methodo-
logical expertise).12 An initial list of items for consideration was
identified from these sources and supplemented with information
from UK-based clinical trial unit HEAP standard operating pro-
cedures (SOPs) supplied by request to the project team. The
project team met to discuss the “long list,” and items were
examined for significant overlap. Similar items were combined;
for example, “Scope of HEAP,” “General principles,” and “Purpose
of HEAP” were combined as “Purpose of HEAP.” Items were split if
they covered 2 or more distinct topics. Each item was briefly
summarized in a statement (eg, the item “Valuation of resource-
use data” was summarized as “For each resource measured,
describe how the unit cost will be derived”), and an example of
how the item might appear in a HEAP was prepared based on
excerpts from the HEAP examples. This list was then used to form
the basis of a 2-round electronic Delphi survey, which was
developed using REDCap data capture software13 and hosted at
the University of Bristol. Items were grouped into thematic sec-
tions within the survey, each of which was presented to partici-
pants on a separate page. Only fully completed surveys were
analyzed. Both rounds of the survey were tested and piloted by
the project team, and improvements inwording to aid clarity were
made after piloting.
Participants and Recruitment
Potential Delphi participants were recruited using the
HEALTHECON-ALL mailing list through a generic invitation toparticipate in the survey by following a web link. Email invitations
(n = 90) were also sent directly to health economists, including
attendees of the 2015 HEAPs workshop in Bristol, and to appro-
priate unit leads in the UK and internationally. Prospective par-
ticipants were asked to have had some experience with HEAPs.
Completion of the first round of the HEAPs Delphi survey was
considered to represent informed consent to participate in the
project. Participants’ professional details were requested at the
start of the survey and included number of years’ experience in
health economics, number of HEAPs worked on, country of work,
and type of economic analysis mainly undertaken by the
participant.
Delphi Survey
Round 1
Participants were asked to rate each item on a Likert scale from
1 to 9, where 1 represented an item that is nonessential and 9
represented an item that must be included in a HEAP. Free-text
boxes at the end of each section allowed participants to suggest
additional items and provided an opportunity to add any further
comments or feedback. A reminder email was sent to the
HEALTHECON-ALL mailing list 2 days before the 2-week deadline
in the original email. Results from round 1 were analyzed and
used to develop the list of items to be included in a second round.
The number and percentage of people rating an item as of high
importance (defined as 7 to 9) and as of low importance (defined
as 1 to 3) were calculated, along with the mean (standard devia-
tion) and median score for each item. Criteria for dropping items
prior to round 2 were predefined based on previous published
work.5 Items were dropped if.50% of participants rated an item 3
or lower and ,15% rated it 7 or higher. A new item would be
added to the second round if it was suggested by more than 10% of
respondents.
Round 2
All participants who had completed round 1 of the survey were
emailed a web link to complete a personalized version of round 2
(Fig. 1) within a specified 2-week time period for response.
Summary statistics of the round 1 results were presented (mean,
standard deviation, median, range), alongside a reminder of the
participant’s own response in round 1. Minor changes to wording
from round 1, made on the basis of the feedback provided, were
highlighted in the round 2 survey. Participants were asked to
rerate each item taking into consideration the feedback from
round 1. The option to provide qualitative feedback was provided
at the end of the second-round survey, and participants were
asked to confirm whether they would be available and willing to
attend a final item selection meeting. Where required, a reminder
email was sent 2 days before the 2-week survey submission
deadline, specifying the closing date. If participants did not
respond after the reminder email, they were contacted by tele-
phone, using publicly available work contact information.
Following round 2, agreement was assessed using the RAND/
UCLA approach, which takes into account not only the score itself,
but also the degree of dispersion among responses.14 The pro-
portion of respondents rating items high and low were calculated,
and the predefined consensus criteria (Table 1) were applied. For
round 2, items were determined as having achieved “consensus
in” if 70% or more participants scored the item as 7-9 and less than
15% of participants scored the item as 1-3. The criteria were the
same as those used to determine the content of SAPs for ran-
domized controlled trials5 and in other contexts (eg, 15).
However, as these criteria are essentially an arbitrary choice, the
RAND/UCLA appropriateness method14 (which combines the
Figure 1. Extract from round 2 of Delphi survey.
Table 1. Predefined consensus classification criteria for round 1 (R1) and round 2 (R2) of the Delphi survey.
Consensus classification Description Definition
Consensus in Consensus that component should be
included in the HEAP
50% (R1) or 70% (R2) or more participants
scoring as 7 to 9 AND ,15% participants
scoring as 1 to 3
Consensus out Consensus that component should not be
included in the HEAP
50% (R1) or 70% (R2) or more participants
scoring as 1 to 3 AND ,15% participants
scoring as 7 to 9
No consensus Uncertainty about importance of
component
Anything else
-- 3
Figure 2. Delphi survey participant numbers. (R1 = round 1, R2 = round 2).
Survey link sent to individuals on
HEALTHECON-ALL mailing list
and 90 named individuals.  
Round
1
Round
2
Individual link sent to 62
participants who completed R1
62 usable responses received
from participants
96 surveys started in total
48 participants completed R2
Email reminder sent to 38 non-
responders
24 participants completed R2
before 2 week deadline
Email reminder sent to all
non- responders after 2
weeks
29 further surveys started
10 further responses received
after 2-week email reminder
14 further responses received
9 could not be contacted
5 were contacted but couldn’t
complete survey (moving jobs,
on annual leave, striking, felt
survey not relevant to them)
28 non-responders contacted by
telephone
67 surveys started in total
34 surveys started but were
not completed
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to inform discussion in the final item selection meeting. Medians
of 7-9 alongside agreement suggested inclusion, medians of 1-3
alongside agreement suggested exclusion, and medians of 4-6
with or without agreement represented an unclear outcome.
Final Item Selection Meeting
After round 2 of the Delphi survey, a final item selection
meeting was held in Bristol (March 19, 2018) to discuss the results
of the Delphi survey and to reach an inclusion decision on items
lacking consensus. The meeting was attended by the following
expert panel: the HEAP project team (comprising 8 health econ-
omists and one Delphi coordinator), 2 Delphi participants, and 2
clinical trial unit representatives. A Delphi expert was available for
consultation by telephone if required. Items where consensus had
been achieved were discussed briefly for group confirmation and
agreement. The expert panel members were asked to vote on
items that had not reached consensus in the Delphi survey. After
discussion of the reasons for or against inclusion, panel members
voted using TurningPoint software to allow for anonymous re-
sponses.16 The panel was asked to vote for one of the following
possible outcomes: (1) to keep an item in the essential HEAP list;
(2) to place the item on an optional list; or (3) to take the item out
of the HEAP completely. Votes were cast by the 9 healtheconomists (except the meeting chair) present. Items were
selected (or otherwise) on the basis of a simple majority; where
there was a tie, further discussion took place before a repeat vote
was taken.
Results
Initial “Long List”
106 potential items for inclusion in the Delphi survey were
extracted from a total of 18 HEAPs and 4 SOPs. Following dedu-
plication and merging of similar items, an initial long list of 72
items was created, and organized into 8 sections: Administrative
information, Trial introduction and background, Economic
approach/overview, Economic data collection and management,
Economic data analysis, Modeling and value of information ana-
lyses, Reporting/publishing, and References and appendices.
Delphi Survey
The numbers of participants responding to each round of the
survey are shown in Fig. 2. Piloting of the round 1 survey indicated
that it was relatively straightforward to understand, taking around
20 minutes to complete. Sixty-two participants provided complete
responses to round 1. Most participants carried out their health
Table 2. Characteristics of Delphi panel participants.
Round 1
(n = 62)
Round 2
(n = 48)
Number (%) Number (%)
Country of health economics work
UK 48 (77.4) 38 (79.1)
Other Europe 10 (16.1) 7 (14.6)
Austra/Asia 3 (4.8) 2 (4.2)
Other 1 (1.6) 1 (2.1)
Professional background
Health economist 60 (96.8) 47 (97.9)
Other 2 (3.2) 1 (2.1)
Number of HEAPs experienced
0 4 (6.5) 4 (8.3)
#5 24 (38.7) 17 (35.4)
.5 32 (51.6) 25 (52.1)
No answer 2 (3.2) 2 (4.2)
Main work setting
Academia 53 (85.4) 40 (83.3)
Industry 4 (6.5) 3 (6.3)
Other 4 (6.5) 4 (8.3)
No answer 1 (1.6) 1 (2.1)
Main analysis type
Within trial analysis 25 (40.3) 21 (43.7)
Model based on a trial 8 (12.9) 6 (12.5)
Both 29 (46.8) 21 (43.7)
Years in health economics
,5 11 (17.7) 7 (14.6)
5-10 14 (22.6) 13 (27.1)
11-20 26 (41.9) 21 (43.7)
.20 11 (17.7) 7 (14.6)
-- 5economics work in the UK (77%), other European countries (16%),
and Australasia (5%); other participant characteristics are shown
in Table 2. Comments from participants included suggestions for
new items and improvements to wording or examples, justifica-
tions and explanations for particular ratings, and some concern
over duplication with material in other trial documentation.
Comments on the modeling section drew attention to the diffi-
culty of prespecifying model analyses that may be dependent on
trial results.
The mean (standard deviation) item score in round 1 was 7.3
(2.1), with individual item means ranging between 5.1 (2.3) and
8.8 (0.5). Applying the predefined consensus criteria for round 1
(.50% rating an item 7-9, ,15% rating it 1-3) resulted in 56 items
remaining in the HEAP. Sixteen items did not reach consensus, and
no items met the criteria for being dropped (.50% rating the item
1-3 and ,15% rating it 7-9); full round 1 results are given in
Table 3. None of the new items proposed by participants in the
comments sections met the inclusion requirement of being sug-
gested by .10% of participants. Therefore, because no items were
voted out in round 1, all 72 items were carried forward to round 2,
allowing participants to rate all items in context. A small number
of changes (n = 7) were made to the wording of items.
Round 2 of the survey was completed by 48/62 participants
(77.4%). Nonresponders to round 2 (n = 14) rated items in round 1
at a mean of 7.6 compared to 7.3 for responders (P = .34). Reasons
given over the telephone from nonresponders for not completing
round 2 included changing jobs, on annual leave, on strike (UK
academics were in dispute with employers over changes to the
academic pension scheme at the time of the survey), or they felt
the survey was not relevant to them. Nine participants could notbe contacted by telephone. RAND/UCLA approach agreement
criteria14 were met for all of the items, and standard deviations
were lower for all items in round 2 than in round 1. The mean
(standard deviation) item score in round 2 was 7.4 (1.9). Com-
ments in round 2 focused on explaining some of the scores given,
and they reiterated an intention to avoid overlap with other trial
documentation. The issue of divergent results and conclusions (ie,
an analysis that does not find a clinical outcome difference be-
tween intervention and comparator but finds that the interven-
tion is likely to be cost-effective) was also raised.
At the end of round 2, 53 items met the consensus conditions
for appearing in the final HEAP template and 19 items did not
reach consensus. No items met the consensus criteria for being
dropped from the HEAP.
Final Item Selection Meeting
Discussions at the final item selection meeting resulted in 5
items being voted out of the HEAP (Table 3). Of these, 4 had not
reached consensus in the Delphi survey; votes were 8 in favor of
dropping the item and 1 in favor of putting it on the optional list in
each case. The remaining item (“post hoc analyses”) had reached
the consensus criteria for inclusion in the Delphi survey. However,
following discussion of the merits of its inclusion, the group felt
that post hoc changes (ie, those occurring after any analysis has
begun, or study intervention allocation has been unblinded)
should be documented in the trial outputs rather than in the HEAP
itself, and that a priori changes (ie, before first analysis) to the
HEAP were already covered in the administrative section. The item
was therefore voted out by a majority: 6 votes for exclusion and
only 3 votes for inclusion.
For 7 items that had not reached consensus in the Delphi
survey, voting indicated that they should be included in the final
HEAP. For 1 of these items (“Data validation and cleaning”), the
inclusion vote was dependent on a change in wording and a move
to a different section. Nine items were not voted essential but
were considered suitable for an optional list; of these, 8 had not
reached consensus in the Delphi survey, and the ninth only just
achieved consensus.
A total of 58 items were therefore designated for inclusion in
the HEAP essential list. The final outcomes for each item are given
in Table 3. The current HEAP template headings, descriptions, and
example texts are given in the Supplemental Materials found at
https://doi.org/10.1016/j.jval.2020.10.002; updated versions with
refinements to the examples elicited through practical application
of the template will be deposited with the University of Bristol
research repository.17Discussion
In this study, we used Delphi methodology to derive a
consensus opinion on a minimum set of items that should be
included in a HEAP for an economic evaluation conducted
alongside an RCT. The 58 selected items form a coherent set of
information covering administrative details, trial particulars, de-
tails of the economics study methods (including data collection,
data management and analysis, and modeling approaches), and
reporting aspects. A further 9 items were deemed important to
consider including in a HEAP, although not essential. Good
agreement on the relative importance of individual items was
found among participants in the Delphi survey.
The study benefited from a panel of health economists from a
variety of backgrounds, many of whom had substantial experience
of working with HEAPs. Although drawn from an international
pool, the participants were predominantly from the UK and
Table 3. Results from the Delphi survey.
Item Round 1
Median
score
Round 1 Item
IN/OUT or NO
CONSENSUS
Round 2
Median
score
Round 2
Number (%)
rated 7 to 9
Round 2
Number (%)
rated 1 to 3
Round 2 Item
IN/OUT or NO
CONSENSUS
Item
status
after final
voting
Title 8 IN 8 39 (81.3) 3 (6.3) IN IN
Trial registration number 8 IN 8 42 (87.5) 1 (2.1) IN IN
Source of funding 8 IN 8 40 (83.3) 2 (4.2) IN IN
Purpose of health economics analysis
plan (HEAP)
8 IN 8 37 (77.1) 2 (4.2) IN IN
Sponsor approval 6.5 NO CON 6 14 (29.2) 5 (10.4) NO CON OUT
Trial protocol version 7 IN 7 37 (77.1) 1 (2.1) IN IN
Trial statistical analysis plan (SAP)
version
7 IN 7 34 (70.8) 1 (2.1) IN IN
Trial HEAP version 8 IN 8 42 (87.5) 1 (2.1) IN IN
HEAP revisions 7 IN 7 35 (72.9) 2 (4.2) IN IN
Table of contents 6 NO CON 5 11 (22.9) 9 (18.8) NO CON OPTIONAL
LIST
Abbreviations/glossary of terms/
definitions
6.5 NO CON 6 18 (37.5) 5 (10.4) NO CON OPTIONAL
LIST
Roles and responsibilities 7 IN 7 33 (68.8) 0 (0) NO CON IN
Signature(s) of person(s) writing HEAP
(and date)
6 NO CON 6 16 (33.3) 9 (18.8) NO CON IN
Signature of senior health economist
(HE) who is guarantor of the economic
evaluation (and date)
6 NO CON 6 18 (37.5) 6 (12.5) NO CON IN
Signature of the chief investigator for
the trial
6 NO CON 6 15 (31.3) 9 (18.8) NO CON IN
Trial background and rationale 7 IN 7 35 (72.9) 2 (4.2) IN IN
Aim(s) of the trial 8 IN 8 38 (79.2) 1 (2.1) IN IN
Objectives and/or research
hypotheses of the trial
7 IN 8 37 (77.1) 2 (4.2) IN IN
Trial population 7 IN 7 41 (85.4) 2 (4.2) IN IN
Intervention and comparator(s) 9 IN 9 47 (97.9) 1 (2.1) IN IN
Trial design 8 IN 8 45 (93.8) 1 (2.1) IN IN
Trial start and end dates 7 IN 7 33 (68.8) 3 (6.3) NO CON IN
Aim(s) of economic evaluation 9 IN 9 48 (100) 0 (0) IN IN
Objectives(s)/hypotheses of economic
evaluation
9 IN 9 47 (97.9) 0 (0) IN IN
Overview of economic analysis 9 IN 9 48 (100) 0 (0) IN IN
Jurisdiction 7 IN 7 38 (79.2) 2 (4.2) IN IN
Perspective(s) 9 IN 9 47 (97.9) 0 (0) IN IN
Time horizon 9 IN 9 48 (100) 0 (0) IN IN
Monitoring collection of health
economic data
7 NO CON 7 34 (70.8) 4 (8.3) IN OPTIONAL
LIST
Database management 7 NO CON 7 25 (52.1) 5 (10.4) NO CON OPTIONAL
LIST
Data entry 7 NO CON 6 23 (47.9) 4 (8.3) NO CON OPTIONAL
LIST
Data cleaning for analysis 7 IN 7 33 (68.8) 5 (10.4) NO CON IN
Data archiving 6.5 NO CON 6 17 (35.4) 4 (8.3) NO CON OPTIONAL
LIST
Statistical software used for HE
analysis
7 IN 7 35 (72.9) 3 (6.3) IN IN
Identification of resources 9 IN 9 47 (97.9) 0 (0) IN IN
continued on next page
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Table 3. Continued
Item Round 1
Median
score
Round 1 Item
IN/OUT or NO
CONSENSUS
Round 2
Median
score
Round 2
Number (%)
rated 7 to 9
Round 2
Number (%)
rated 1 to 3
Round 2 Item
IN/OUT or NO
CONSENSUS
Item
status
after final
voting
Measurement of resource use data 9 IN 9 48 (100) 0 (0) IN IN
Valuation of resource use data 9 IN 9 45 (93.8) 0 (0) IN IN
Identification of outcome(s) 9 IN 9 48 (100) 0 (0) IN IN
Measurement of outcome(s) 9 IN 9 48 (100) 0 (0) IN IN
Valuation of outcome(s) 9 IN 9 47 (97.9) 0 (0) IN IN
Analysis population 9 IN 9 45 (93.8) 0 (0) IN IN
Timing of analyses 8 IN 8 40 (83.3) 1 (2.1) IN IN
Discount rates for costs and benefits 9 IN 9 43 (89.6) 1 (2.1) IN IN
Cost-effectiveness threshold(s) 8.5 IN 8 39 (81.3) 4 (8.3) IN IN
Statistical decision rule(s) 8 IN 8 39 (81.3) 3 (6.3) IN IN
Analysis of resource use 9 IN 9 43 (89.6) 0 (0) IN IN
Analysis of costs 9 IN 9 46 (95.8) 0 (0) IN IN
Analysis of outcomes 9 IN 9 47 (97.9) 0 (0) IN IN
Missing data 9 IN 9 48 (100) 0 (0) IN IN
Analysis of cost-effectiveness 9 IN 9 47 (97.9) 0 (0) IN IN
Sampling uncertainty 9 IN 9 47 (97.9) 0 (0) IN IN
Subgroup analysis/Analysis of
heterogeneity
9 IN 9 45 (93.8) 0 (0) IN IN
Sensitivity analyses 9 IN 9 47 (97.9) 0 (0) IN IN
Post hoc analyses 8 IN 8 38 (79.2) 2 (4.2) IN OUT
Extrapolation or decision analytic
modeling
9 IN 9 46 (95.8) 0 (0) IN IN
Model type 9 IN 9 44 (91.7) 1 (2.1) IN IN
Model structure 8.5 IN 8 44 (91.7) 1 (2.1) IN IN
Treatment effect beyond the end of
the trial
8.5 IN 8 42 (87.5) 2 (4.2) IN IN
Other key assumptions 8 IN 8 41 (85.4) 1 (2.1) IN IN
Methods for identifying and
estimating parameters
8 IN 8 43 (89.6) 1 (2.1) IN IN
Model uncertainty 9 IN 9 45 (93.8) 1 (2.1) IN IN
Model validation 8 IN 8 42 (87.5) 1 (2.1) IN IN
Subgroup analyses/Heterogeneity 8 IN 8 41 (85.4) 2 (4.2) IN IN
Value of information analysis 6.5 NO CON 6 20 (41.7) 6 (12.5) NO CON OPTIONAL
LIST
Responsibility for health economic
results and reporting
7 NO CON 6.5 24 (50) 4 (8.3) NO CON OUT
Reporting standards 7 IN 7 35 (72.9) 2 (4.2) IN IN
Reporting deviations from the HEAP 8 IN 8 40 (83.3) 2 (4.2) IN IN
References to trial and statistical
master file
6 NO CON 6 13 (27.1) 9 (18.8) NO CON OUT
References to other trial documents 6.5 NO CON 6 19 (39.6) 5 (10.4) NO CON OPTIONAL
LIST
Appendices: Resource use data
collected
7 IN 7 33 (68.8) 4 (8.3) NO CON IN
Appendices: Reporting checklists 6 NO CON 6 13 (27.1) 12 (25) NO CON OUT
Appendices: Illustrations 5 NO CON 5 3 (6.3) 13 (27.1) NO CON OPTIONAL
LIST
-- 7
8 VALUE IN HEALTH - 2020working in academia. The use of the international HEALTHECON-
ALL mailing list explicitly targeted broader participation; however,
the preliminary workshop in 2015 had already indicated that
HEAPs were less widely used alongside RCTs outside the UK, and
even less so outside Europe. Although the UK-centric nature of the
participants may have an impact on the generalizability of the
results, we believe that the template will have applicability
beyond the UK. The participation of the project team in the final-
item selection meeting is not expected to have led to bias in the
selected items given the prospective specification of the process
and full description of results at each step. Consensus criteria were
defined in advance of the survey in order to adhere to established
Delphi methods. The sample size of 48 individuals completing
both rounds is reasonable, given that even small sample sizes for
Delphi studies can give reliable outcomes.18 Two rounds of the
Delphi survey were adequate, as agreement based on the RAND/
UCLA criteria was achieved for all items following the second
round. Owing to the timing of the survey, which spanned the UK
Christmas holiday season, the 2 rounds were held two and a half
months apart; however, participants in round 2 were reminded of
their own scores from the first round, attrition was relatively low
(over 75% of respondents completed both rounds), and there was
no evidence from comments in the second round that the timing
was an issue.
The inclusion of modeling items led to considerable discussion,
both among the project team and in the comments provided
within the Delphi survey. Respondents pointed out that it is not
uncommon for model structures to change during a project as
evidence external to the trial evolves; prespecifying methods
could be unhelpfully limiting for model analyses given that
modeling is carried out for the purpose of decision analysis rather
than trial reporting and must be responsive to the information
needs of decision makers. However, all the modeling items (except
value of information items) were rated highly in the Delphi survey
with consensus that they should be included in a HEAP (although
it should be noted that approximately 40% of the participants
worked mainly on within-trial economic analyses). As described
by one survey participant, this section should be treated as a
model conceptualization rather than a prescriptive outline of the
entire model, particularly given that the evidence required for a
model may not be available at the time of writing the HEAP; the
examples given alongside the items were constructed to demon-
strate this.
Concerns over the credibility of clinical trial and other scientific
results have led to calls for adopting measures designed to
improve conduct and reporting of studies.19 The suite of docu-
mentation that is now associated with RCTs (including the pro-
tocol, SAP, data-sharing requirements, and reporting of results)
aims to improve the transparency and reproducibility of clinical
research. Preparation of the HEAP should be carried out in the
context of other trial documentation and in consultation with
statisticians to ensure consistency of approaches and terminology
with the SAP. In this study, we aimed to identify a comprehensive
list of items that could be used in a standalone HEAP. Many of the
items are administrative or relate to the trial itself rather than the
economic evaluation specifically. There is inevitably some overlap
with the SAP and other documentation, and, in practice, some
items could be cross-referenced.
Attendees at the 2015 HEAPs workshop felt that HEAPs need to
be implemented with some flexibility. Where changes are neces-
sary, the final study report should acknowledge and justify any
deviations from the HEAP, such as changes in best practice
methods. Flexibility may also be required for novel trial designs;
although the list identified here was not developed with any
particular trial design in mind, it may be necessary to addadditional items (eg, for adaptive or factorial trials). It is also
important to note that writing a HEAP requires time that must be
accounted for in resourcing projects. Finally, the guidance pro-
duced for SAPs states that “SAPs should be made publicly avail-
able.”5 In line with this advice, we suggest the same should apply
to HEAPs, and that HEAPs (if not published) should be deposited in
accessible repositories.
While the key purpose of a HEAP is to increase transparency
and reduce the potential for bias, preparation of a HEAP confers
additional benefits. For example, it can increase the efficiency of
the analysis phase, highlight potential issues at an early stage, and
foster good communication between health economists and the
wider trial team. In the event of staff turnover, a comprehensive
HEAP can protect the trial team against knowledge loss. It may be
necessary to revise the list of essential HEAP items in the future to
reflect conceptual, methodological, and practical advances or
changes in the field.Conclusions
The aim of a HEAP is to prevent bias in the results of economic
evaluations arising from selective reporting or analyses being
cherry-picked once the data have been examined, and to enable
reproducibility. However, it is also important that the documents
are not overly bureaucratic and burdensome for researchers. This
study generated 58 core items that were considered essential for
inclusion within a HEAP via expert consensus opinion. The list
captures all the most important items but is considered a
manageable size; these essential items form a template HEAP that
will provide guidance for economic evaluations in RCTs. HEAPs
should now be implemented more widely and consistently by the
health economics community.Supplemental Materials
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